EFFECTIVENESS OF NOVEL PHARMACOTHERAPY STRATEGIES IN PATIENTS WITH CHRONIC HEART FAILURE

Chronic heart failure (CHF) remains a leading cause of morbidity and mortality worldwide, necessitating the development of effective pharmacotherapy strategies. Recent studies have highlighted the potential of novel pharmacological approaches, including SGLT2 inhibitors, angiotensin receptor-neprilysin inhibitors (ARNIs), and combination therapies, in improving cardiac function, reducing hospitalizations, and enhancing patients’ quality of life [1,2]. These strategies demonstrate significant benefits in symptom control, ejection fraction improvement, and long-term survival compared to conventional treatment. Challenges such as patient adherence, comorbidities, and individualized responses require careful monitoring and tailored therapeutic plans. Overall, integrating these modern pharmacotherapy strategies into routine CHF management offers promising outcomes and may redefine standard care protocols [3,4].